Millennium Management
AARD

Millennium Management’s Aardvark Therapeutics AARD Stock Holding History

Millennium Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371K Sell
98,334
-385,006
-80% -$3.99M ﹤0.01% 4917
2025
Q4 		$6.34M Buy
483,340
+163,717
+51% +$2.04M ﹤0.01% 2750
2025
Q3 		$4.25M Buy
+319,623
New +$3.6M ﹤0.01% 3307
2025
Q2 		– Sell
-65,640
Closed -$493K – 6460
2025
Q1 		$493K Buy
+65,640
New +$737K ﹤0.01% 4820

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management's AARD Position: Q1 2026 in Review

Millennium Management reduced its Aardvark Therapeutics (AARD) stake by 80% in Q1 2026, selling an estimated $3.99M and leaving 98,334 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #4917.

Millennium Management first reported a position in AARD in Q1 2025 and has held it in 4 quarters since. The position peaked at $6.34M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Millennium Management held 98,334 shares of Aardvark Therapeutics worth $371K as of Q1 2026.
  • Millennium Management sold 385,006 Aardvark Therapeutics shares in Q1 2026, an estimated $3.99M.
  • Aardvark Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4917 holding.
  • Millennium Management first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Millennium Management's Aardvark Therapeutics position peaked at $6.34M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.